Sandan, I really don't mind questions or varying points of view at all. But some of the questions just can't be answered right now. I've asked Mr. Schneiderman a few questions about RapiMeds and his reply was, "I can't reply at this time news will follow". I'm find with that. I let the man do his job. As to varying points of view, I welcome it. And, being a proud member of the CORE, I do allow a lot of latitude. However, when people get nasty and start tearing down a stock I believe in and individuals I respect, they will hear back from me. I have been playing the penny stocks now for near three years and can say I have done quite well. Oh, I've also lost on a few real losers as well. But, I picked SCRC to be a winner and I know it will be. I've been in the pharma industry for 37 years and I've seen company's business plans change mid stream on several occasions, just like we saw with compounding and SCRC. Mr. Schneiderman's decision to explore and develop compounding as a revenue steam has been brilliant. And I know RapiMeds are still alive and well, it's just taking longer to develop than we all thought. All the revenue streams he eluded to on his interview will soon pay off and we the investors will be the beneficiaries of this success.